AzTrials
AzTrials

Venous UlcerNCT00847002

Flexitouch Treatment for Venous Ulcers

A study testing Standard Wound Care and Flexitouch System with Standard Wound Care in people with Venous Ulcer, run by Tactile Systems Technology, Inc. at 2 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in 1. greater complete healing 2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Venous Ulcer
What is being tested?
Standard Wound Care and Flexitouch System with Standard Wound Care
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
2 sitesUnited States
Study dates
Sep 2007to Aug 2010
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient must be at least 18 years old
  • The ulcer maximum length x its maximum width must be greater or equal to 0 cm2
  • The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.
  • The ulcer must have been present for more than 1 month.
  • The ulcer must be located below the knee.
  • The ulcer bed must have some viable tissues with some granulation tissue.

Who cannot join

  • Exposed bone, tendon, or fascia
  • Severe rheumatoid arthritis
  • History of radiotherapy to the ulcer site
  • Uncontrolled congestive heart failure
  • Receiving corticosteroids or immune suppressive therapy
  • History of collagen vascular disease
Show all 21Show fewer
  • Known malnutrition (albumin<3.0 g/dL). If malnutrition is suspected, the albumin level should be checked to determine if the patient meets the albumin criterion.
  • The ulcer is clinically infected. However, patients may be entered into the study after successful treatment of infection.
  • Known uncontrolled diabetes (HgbA1c > 8%). If uncontrolled diabetes is suspected, the Hgb A1c should be checked to determine patient eligibility.
  • Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).
  • Known arterial insufficiency (Ankle-brachial index < 0.7, or TcPO2 < 35 mm Hg, or Toe-brachial index < 0.4). If peripheral vascular disease is suspected, vascular lab testing should be checked to determine patient eligibility.
  • Active sickle cell disease
  • Unable to comply with the procedures described in the protocol
  • Enrolled in a clinical evaluation for another investigational wound-care device or drug
  • Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months
  • Pregnancy, suspected or confirmed
  • Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing
  • Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy
  • History or pulmonary embolism
  • Poorly controlled asthma
  • Pulmonary Edema

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Wound Healing and Hyperbaric Center

    College Station, Texas, 77845

  • VA Medical Center

    Minneapolis, Minnesota, 55417

Other trials in United States

About this study

Official title: A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers

This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in

  1. greater complete healing
  2. greater percentage reduction in ulcer area
  3. reduced time to complete healing, as compared to the use of standard treatment alone
  4. a greater reduction in affected leg volume as compared to standard treatment alone.
Read the detailed description

A pilot randomized trial of Flexitouch® as an adjunctive treatment for venous ulcers

Objectives To determine if the Flexitouch® compression therapy system, when added to standard venous ulcer (VU) treatment, results in: 1. Greater complete healing at 12 weeks as compared to standard treatment alone. 2. Greater percentage reduction in ulcer area at 12 weeks as compared to standard treatment alone. 3. Less time to complete healing as compared to standard treatment alone 4. A greater reduction in the leg volume of the affected leg

Hypothesis We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in

  1. greater complete healing, 2) greater percentage reduction in ulcer area 3) reduced time to complete healing, as compared to the use of standard treatment alone, and 4) a greater reduction in affected leg volume as compared to standard treatment alone.

Patient recruitment, eligibility, and exclusions Patients who present at our clinic with a venous leg ulcer, as judged by clinical presentation and history, will be recruited for participation in this research study. For this pilot study a total of 16 patients will be recruited.

Protocol and Procedures After verifying eligibility and administering an approved informed consent, patients will be randomized to one of the study arms (A or B). Study patients will be seen one or two times per week (per physician's discretion) for 12-weeks for standard wound care and treatment. For both groups, sustained compression will be achieved with the FarrowWrap™ Classic device. This device will be worn continuously except during the twice-weekly treatments and when Flexitouch therapy is being undertaken (Group B only). Group B will use Flexitouch at home every day (twice daily); Group A will not use Flexitouch. Once per week, treatment and parameter assessments will be undertaken as described below.

Standard Wound Care and Treatment Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment. For venous ulcer treatment it is applied at full stretch. The patient will be given instructions as to how to apply the FarrowWrap at home.

Flexitouch System and its Use Patients who have been randomized to Group B will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action. The system consists of a controller unit with four eight-port connectors and a garment set for the trunk and leg. The garments are placed around the trunk and affected limbs and are connected to the controller by a tubing harness. The controller inflates and deflates the air chambers within the garments in a pre-determined pattern to assist the lymphatics in moving the fluid into adjacent lymph node regions of the trunk. The controller inflates individual chambers in the garments for 1-3 seconds per inflation.

Potential Treatment modifications The patient's welfare, as determined by the principal investigator, will take precedence over any study procedures. Any interventions necessary for the patient's welfare will be undertaken as necessary.

Wound Photography The wound will be photographed using a digital camera with zoom capability supplied by the sponsor of this study. All photographs will be taken with the camera pointing directly down to the wound such that the angle between the camera and the plane-of-the wound is as near to 90o as possible. Flash will be avoided if there is adequate lighting. The vertical distance from the wound to the camera is not critical but a distance of about 20 cm will be used when possible. Prior to taking photographs, a suitable dimensional scale or calibration standard will be placed in contact with the skin near, but outside a wound margin. In the case of a one-dimensional scale, it will be placed above or below the wound, and positioned along the long dimension of the wound. A suitable calibration standard will be supplied by the sponsor of this study. The framing of the photo will be such as to include 1) the complete wound bed, 2) a small sampling of the surrounding periwound tissue and 3) the calibration standard or scale. The composed image, as viewed through the camera LCD viewport, will be as large as possible while still including the required elements. The camera will be oriented such that the horizontal dimension of the LCD viewport is parallel to the horizontal calibration scale on the leg.

Wound Tracing After photographing, the wound margins will be traced by placing a transparent grid over the wound. The grid is a commercial product (E-Z Graph) that is designed for this purpose. It consists of two layers; a bottom layer which is in contact with the wound and an upper layer on which tracing is done using a colored pen. The upper layer has a grid system with 1 x 1 cm squares imbedded into the material. After tracing the bottom layer is discarded. The patient's study ID, visit number and visit date are then recorded on a space provided on the upper tracing grid.

Assessment of Leg Volumes Leg volumes of both right and left legs from ankle to knee will be determined. This is done using a calibrated tape measure (Gulick-type) to measure circumferences at 4 cm intervals starting at the malleoulus and progressing toward the knee. From these circumference measurements, limb volumes will be determined using the well established truncated cone model together with a validated software algorithm. Using this method the wound assessor enters the circumferences into a standardized form and the appropriate volumes are automatically determined.

Assessment of Complete Wound Healing At each visit the wound will be carefully inspected by the Principal Investigator and the presence or absence of complete wound healing noted and recorded. For this study, wound healing will be considered to occur when the wound is fully covered with epithelium and there is no drainage. In addition, at each visit, a study-related case report form will be completed by the Principal Investigator to document various clinical features of the wound and to note any relevant study-related actions or events. This form will be embedded within password protected software so that most wound descriptors will be able to be entered and documented with a simple mouse click.

Analysis of Wound Areas and Related Parameters Wound Areas by Photo Images: The digital images of the wound will be coded by the Principal Investigator by suitably renaming each photographic image file with a unique identifier. He will keep a record of these coded file names and the group, patient, and visit date and number to which they correspond. A copy of each image file will be made and stored on a CD. The CD will be sent to a scientific advisor who works with the study sponsor. The advisor will be responsible for the analyses of the images, including the determination of wound areas via computerized planimetry and for subsequent data and statistical analyses. The analyst will blind as to which actual group the images correspond. At the completion of the data acquisition phase of the study, the analyst will be told which images belong to common groups, but he will still not know which of the common groups belong to which arm of the study. He will thus remain blind during the subsequent statistical analyses.

Wound Areas by Tracings: As a complementary comparison approach, wound areas will also be assessed from the wound tracings. The analyst will be supplied with copies of the coded tracings. The tracings will then be scanned and the wound areas determined by computerized digital planimetry as previously described. Areas determined by this method will serve as a check measurement and will be used as a backup in those cases (if any) in which photographic quality is inadequate.

Leg Volumes: In addition to photographs and tracings, the analyst will be supplied with coded electronic copies of the leg circumference forms. This data will be used to determine if, and to what extent, changes in leg volume or edema occur, and if there are differences in these parameters between groups A and B.

Wound Descriptors: A coded electronic version of the case report form, containing wound descriptor parameters data, will be supplied to the analyst. This information will be used primarily in the final analysis to summarize the clinical progression of the wounds.

Conditions
Venous Ulcer
Being tested
Standard Wound Care, Flexitouch System with Standard Wound Care
Keywords
Flexitouch system, FarrowWrap, venous stasis ulcer
Medical subject headings
Varicose Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard Wound CareDevice

    Also called Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings

  • Flexitouch System with Standard Wound CareDevice

    Also called Flexitouch system, Farrow Wrap, Acticoat, Aquacel Ag, or Mepilex Ag foam dressings

Study groups in NCT00847002
Study groupRoleWhat they receive
Standard Wound CareActive comparatorGentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
Receives: Device: Standard Wound Care
Flexitouch system with Standard Wound CareActive comparatorIn addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
Receives: Device: Flexitouch System with Standard Wound Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wound Healing

    Measured: 12 weeks

Secondary outcomes (1)
  1. Reduction in Leg Volume

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2009 (estimated)
  2. Study startSep 2007
  3. Primary completionAug 2010
  4. Study completionAug 2010

Why it stopped: Lack of Enrollment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00847002
Sponsor's protocol ID
FWFT07312007
Status last verified
Jan 2020
First submitted
18 Feb 2009
Last updated
12 Feb 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Standard Wound Care and Flexitouch System with Standard Wound Care in people with Venous Ulcer, run by Tactile Systems Technology, Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 12 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Jul 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wound Healing (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2020; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in